cenegermin cenegermin cenegermin, sold under the brand name oxervate, also known as recombinant human nerve growth factor (rhngf), is a recombinant form of human nerve growth factor (ngf). in july 2017, it was approved in the european union as an eye drop formulation for the treatment of moderate or severe neurotrophic keratitis in adults. cenegerminclinical datatrade namesoxervateother namescenegermin-bkbj, recombinant human nerve growth factor; rhngf; human beta-nerve growth factor (beta-ngf)-(1-118) peptide (non-covalent dimer) produced in escherichia coliahfs/drugs.commonographmedlineplusa619001license data eu ema: by inn us dailymed: cenegermin pregnancycategory au: b3 routes ofadministrationophthalmicatc codes01xa24 (who) legal statuslegal status au: s4 (prescription only) ca: rx-only / schedule d us: ℞-only eu: rx-only identifierscas number1772578-74-1drugbankdb13926chemspidernoneuniib6e7k36kt8keggd11028chemical and physical dataformulac583h908n166o173s8molar mass13267.15 g·mol−1 as a recombinant form of ngf, cenegermin is a peripherally selective agonist of the trka and lngfr (p75ntr) which must be administered parenterally. the u.s. food and drug administration (fda) considers it to be a first-in-class medication. history it was developed by anabasis pharma, dompé farmaceutici, and ospedale san raffaele. research in addition to neurotrophic keratitis, cenegermin is also under development for the treatment of dry eyes, retinitis pigmentosa, and glaucoma.